- MindWalk Holdings Corp. announced the appointment of **R. Scott Areglado as Chief Financial Officer**, effective **October 20, 2025**.  **[1715925_0001193125-25-244406_hyft-ex99_1.htm:0]** 
- Mr. Areglado brings **over 25 years of financial leadership experience** from the healthcare, life sciences, and technology sectors, having previously served as CFO for BrainsWay Ltd. and iCAD, Inc..  **[1715925_0001193125-25-244406_hyft-ex99_1.htm:0]** 
- At its **2025 Annual General Meeting of Shareholders** on **October 9, 2025**, **Dr. Jennifer Bath, Jon Lieber, and Dirk Witters were elected to the Board of Directors**, and **Davidson & Company LLP was re-appointed as auditor**.  **[1715925_0001193125-25-244406_hyft-ex99_1.htm:0]** 
- **Mr. Kamil Isaev resigned from the Board**, effective immediately, after his re-election bid received 68% withheld votes.  **[1715925_0001193125-25-244406_hyft-ex99_1.htm:0]**

MindWalk Holdings Corp. Appoints New CFO and Announces AGM Results

- MindWalk Holdings Corp.'s Board of Directors has authorized a share repurchase program.  **[1715925_0001193125-25-235316_hyft-ex99_1.htm:0]** 
- The company may repurchase up to **2.3 million common shares**, representing approximately **5%** of its currently issued and outstanding shares.  **[1715925_0001193125-25-235316_hyft-ex99_1.htm:0]** 
- The program is set to commence on **October 15, 2025**, and will run for a twelve-month period, ending no later than **October 15, 2026**.  **[1715925_0001193125-25-235316_hyft-ex99_1.htm:0]** 
- CEO Jennifer Bath stated that the program underscores confidence in MindWalk's future and provides flexibility to repurchase shares when the market price is believed to be disconnected from its intrinsic value.  **[1715925_0001193125-25-235316_hyft-ex99_1.htm:0]**

MindWalk Holdings Corp. Announces Share Repurchase Program

- MindWalk Holdings Corp. announced a significant advancement in its AI-designed GLP-1 therapeutics program, introducing a **first-in-class dual-pathway regimen** for aging and longevity.  **[1715925_0001193125-25-210278_hyft-ex99_1.htm:0]** 
- The company's LensAI™ platform identified a novel connection between GLP-1 biology and a second, non-overlapping pathway, leading to the development of a **proprietary companion therapeutic** for co-administration with its GLP-1 receptor agonists.  **[1715925_0001193125-25-210278_hyft-ex99_1.htm:0]** 
- This strategic evolution positions MindWalk to target the high-growth longevity therapeutics market, which is projected to exceed **$60 billion by 2030**.  **[1715925_0001193125-25-210278_hyft-ex99_1.htm:0]** 
- MindWalk expects to provide updates on lead selection for the companion therapeutic and preclinical combination design parameters in the coming quarters.  **[1715925_0001193125-25-210278_hyft-ex99_1.htm:1]**

MindWalk Holdings Corp. Advances AI-Designed GLP-1 Program for Longevity

- MindWalk Holdings Corp. reported **record revenue of $7.6 million** for its first fiscal quarter of 2026, ended July 31, 2025, representing a **45% year-over-year increase**.  **[1715925_0001193125-25-202898_hyft-ex99_1.htm:0]** 
- The company's **gross margin expanded to 53%**, with **gross profit reaching $4.0 million**, and **net loss improved to $3.0 million** compared to $4.0 million in the prior year.  **[1715925_0001193125-25-202898_hyft-ex99_1.htm:0]** 
- MindWalk strengthened its balance sheet with a **cash balance of $5.0 million** at quarter-end, supplemented by **$16.1 million in net proceeds** from the divestiture of its Netherlands operations.  **[1715925_0001193125-25-202898_hyft-ex99_1.htm:0]** 
- The company completed its rebranding and advanced its dengue vaccine program into preclinical manufacturing, further validating its LensAI platform.  **[1715925_0001193125-25-202898_hyft-ex99_1.htm:0]**

MindWalk Holdings Corp. Reports Record Q1 2026 Revenue and Narrowed Losses

- MindWalk Holdings Corp. (formerly ImmunoPrecise Antibodies Ltd.) reported **revenue of $3.2 million** for the three months ended July 31, 2025, marking a **27.8% increase** compared to the same period in 2024, alongside a **net loss from continuing operations of $4.1 million**.  **[1715925_0001193125-25-202896_hyft-ex99_1.htm:2]** **[1715925_0001193125-25-202896_hyft-ex99_1.htm:7]** 
- The company completed the divestiture of its **IPA Europe B.V.** on **August 6, 2025**, for **$12 million USD**, generating **$11.7 million USD in net proceeds**.  **[1715925_0001193125-25-202896_hyft-ex99_2.htm:3]** **[1715925_0001193125-25-202896_hyft-ex99_1.htm:11]** **[1715925_0001193125-25-202896_hyft-ex99_2.htm:13]** 
- As of July 31, 2025, MindWalk had **$5.0 million in cash on hand** and stated that this amount is **insufficient to fund operations for at least one year**, raising **material uncertainties** regarding its ability to continue as a going concern without securing additional financing.  **[1715925_0001193125-25-202896_hyft-ex99_2.htm:3]** **[1715925_0001193125-25-202896_hyft-ex99_1.htm:7]** **[1715925_0001193125-25-202896_hyft-ex99_1.htm:11]** 
- Management identified a **material weakness** in internal controls over financial reporting as of July 31, 2025, attributed to insufficient resources for complex technical accounting issues, with remediation efforts ongoing.  **[1715925_0001193125-25-202896_hyft-ex99_1.htm:13]**

MindWalk Holdings (HYFT)